Imatinib in neurofibromatosis type 2

BMJ Case Rep. 2013 Jul 8:2013:bcr2013010274. doi: 10.1136/bcr-2013-010274.

Abstract

A 30-year-old man with a 10-year history of neurofibromatosis type 2 (NF-2) and minimal hearing in his left ear, presented with rapidly progressive disease and risk of total hearing loss. He was started on imatinib and achieved stable disease for 4 months, after which the drug was ceased due to toxicity. He was then treated with bevacizumab for 8 months with a best response of stable disease.

Publication types

  • Case Reports

MeSH terms

  • Adult
  • Benzamides / adverse effects
  • Benzamides / therapeutic use*
  • Humans
  • Imatinib Mesylate
  • Male
  • Neurofibromatosis 2 / drug therapy*
  • Piperazines / adverse effects
  • Piperazines / therapeutic use*
  • Protein Kinase Inhibitors / adverse effects
  • Protein Kinase Inhibitors / therapeutic use*
  • Pyrimidines / adverse effects
  • Pyrimidines / therapeutic use*

Substances

  • Benzamides
  • Piperazines
  • Protein Kinase Inhibitors
  • Pyrimidines
  • Imatinib Mesylate